Genuine Biotech Reports Unimpressive Results for Covid Pill
Chinese drugmaker Genuine Biotech reported unimpressive trial results for its Azvudine Covid treatment, prompting a sell-off in related drug stocks.
The response reflected concerns that Azvudine’s clinical trial results fell short of regulatory recommendations. While privately held Genuine Biotech said the drug improved clinical symptoms, Chinese regulators in a February guideline said Covid-19 treatments should reduce severe illness and death.
- MOST POPULAR